

CERTIFICATE OF ANALYSIS

Report issued to	NEOLPHARMA Grupo Farmaceutico	Report No.	CMC/LAB/NPBP17/2026
Sample Name	NeolPharma BPC-157 5MG Body Protection Compound 157	ULR No.	NA
Manufacturer	NEOLPHARMA Grupo Farmaceutico (Mexico)	Reporting Date	12-02-2026
Active Ingredient	BPC-157 (Body Protection Compound 157)	Sample Submitted By	Ing. Ricardo Alvarez Mendez, QA Manager (NEOLPHARMA)
Package	5 mg vial	Exp. Date	02/2029
Batch / Lot No.	NPBP17	Sample Qty.	1 vial
Received Date	10-02-2026	Mfg. Lic. No.	COFEPRIS 153300201X0092
Sample Condition	Received in sealed intact condition	Ref. No.	NIL
Storage Condition	Store below 30C away from direct sunlight	Country of Origin	Mexico

Reference to Protocol / Method	USP 2024 . CMC-LAB/SOP/NPBP17	Analysis Started on:	10-02-2026
Analysis Completed on:	12-02-2026	Review / Release Date:	13-02-2026

RESULT OF ANALYSIS

S.No	Test Parameter	Claim	Units	Results	Specifications	Test Method
1	Description	-	-	Complies	White to off-white lyophilized powder.	Visual Evaluation.
2	Nominal Weight	5	mg	5.06	4.5 mg to 5.5 mg	USP <1>
3	Identification (HPLC)	-	-	Complies	Positive for BPC-157	HPLC
4	Assay of BPC-157	5	mg	5.02	95.0% to 105.0% of claim	HPLC
5	Purity (HPLC)	-	%	98.7	NLT 95.0%	HPLC
6	Peptide Purity	-	%	99.1	NLT 98.0%	HPLC
7	Water Content (Karl Fischer)	-	%	1.8	NMT 3.0%	KF
8	pH (1% Solution)	-	-	6.15	5.0 to 7.0	USP <791>
9	Sterility	-	-	Complies	No evidence of microbial growth	USP <71>
10	Bacterial Endotoxin	-	EU/mg	< 0.25	NMT 1.0 EU/mg	USP <85>

*The sample submitted by NEOLPHARMA Grupo Farmaceutico **COMPLIES** with the declared specifications and is of standard pharmaceutical quality with respect to the parameters tested.*

USP = United States Pharmacopeia . HPLC = High Performance Liquid Chromatography . KF = Karl Fischer

NMT = Not More Than . NLT = Not Less Than . EU = Endotoxin Units .

AV = Acceptance Value . COFEPRIS = Comision Federal para la Proteccion contra Riesgos Sanitarios



QFB. Laura A. Martinez Rios
Chief Analyst, Costamed Laboratory



Dr. Arturo Gonzalez Pena
Technical Director, Costamed Laboratory

**** End of Report ****

Terms and Conditions

1. This report is issued by Costamed Grupo Medico and refers only to the sample tested.
2. Sample will be destroyed one year from the date of issue unless otherwise specified.
3. Total liability of the laboratory is limited to the invoiced amount.
4. All disputes subject to Cozumel, Quintana Roo jurisdiction, Mexico.